Brontictuzumab

• CAT Number: I042445
• CAS Number: 1447814-75-6
• Purity: ≥95%

Brontictuzumab (Cat No.: I042445) is a humanized monoclonal antibody that targets Delta-like ligand 4 (DLL4), a key component of the Notch signaling pathway involved in cell fate determination, angiogenesis, and tumor progression. By binding DLL4, Brontictuzumab inhibits aberrant Notch signaling, disrupting tumor vasculature and cancer stem cell maintenance. It has shown potential in preclinical and early clinical studies for solid tumors, particularly those resistant to conventional therapies. Brontictuzumab represents a promising approach for targeting tumor biology through vascular and stem cell modulation.

Reference

[1]. Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29(7):1561-1568.
[Content Brief]

[2]. Silkenstedt E, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019 Nov 1;38(1):446.
[Content Brief]

[3]. Agnusdei V, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014 Feb;28(2):278-88.
[Content Brief]